- Innovative Medicine
- Immunology
- Rheumatology
Rheumatology
We remain focused on complementing our existing portfolio of large-molecule biologics with novel treatments and oral therapeutics in development to provide new options to patients, through a combination of internal research and development, external collaborations, and industry consortia. We are also advancing research in autoantbody-driven rheumatic diseases, such as sIdiopathic inflammatory myopathies (IIM), Sjögren’s disease (SjD), and Systemic Lupus Erythematosus (SLE).
Keeping patients at the center of everything we do, Johnson & Johnson is committed to tirelessly pushing the boundaries of science to deliver innovative and transformational approaches for heumatic diseases building on the ever-evolving understanding of the immune system.
Disease areas
Newsroom
Featured resources
Getting to the root: Advancing the science of rheumatic disease
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
Patient perspective: Janet Church on navigating Sjögren’s Disease and advocating for change
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
Inside J&J’s many-indication mAb
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
Addressing unmet need in Sjogren’s Disease: J&J at EULAR 2024
You are now leaving jnj.com
The site you are being redirected to is a branded healthcare products website. Please click below to continue to that site.
You are now leaving jnj.com
The site you are being redirected to is a branded healthcare products website. Please click below to continue to that site.
Understanding the burden of psoriatic arthritis fatigue
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson and Johnson, which is governed by its own privacy policy and terms of use.